📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Domain I of ß2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation. (2019)

First Author: Albay A

Attributed to: MICA: Development of PEGylated Domain I of beta-2-glycoprotein I as a new therapeutic agent for the antiphospholipid syndrome funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1177/0961203319851571

PubMed Identifier: 31126213

Publication URI: http://europepmc.org/abstract/MED/31126213

Type: Journal Article/Review

Volume: 28

Parent Publication: Lupus

Issue: 7

ISSN: 0961-2033